The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease

Author： Tábi Tamás   Szökő Éva   Vécsei László   Magyar Kálmán  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.5, 2013-05, pp. : 629-636

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of Selegiline (Deprenyl) in the Treatment of Parkinson's Disease

By Heinonen E.H.  

Drug Safety, Vol. 19, Iss. 1, 1998-07 ,pp. : 11-22

Adis International

Access to resources Recommend Favorite

Orally disintegrating selegiline for the treatment of Parkinson's disease

By Löhle Matthias   Storch Alexander  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2881-2891

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic Optimisation in the Treatment of Parkinson's Disease: An Update

By Nyholm Dag  

Clinical Pharmacokinetics, Vol. 45, Iss. 2, 2006-01 ,pp. : 109-136

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson's Disease

By Deleu D.  

Clinical Pharmacokinetics, Vol. 41, Iss. 4, 2002-01 ,pp. : 261-309

Adis International

Access to resources Recommend Favorite

Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations

By Müller Thomas  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1015-1024

Informa Healthcare

Access to resources Recommend Favorite